Journal of Clinical Medicine,
Journal Year:
2019,
Volume and Issue:
8(4), P. 444 - 444
Published: April 2, 2019
Atopic
dermatitis
(AD)
is
a
long-standing
inflammatory
skin
disease
that
highly
prevalent
worldwide.
Multiple
factors
contribute
to
AD,
with
genetics
as
well
the
environment
affecting
development.
Although
AD
shows
signs
of
barrier
defect
and
immunological
deviation,
mechanism
underlying
not
understood,
treatment
often
very
difficult.
There
substantial
data
patients
have
disturbed
microbial
composition
lack
diversity
in
their
gut
compared
controls,
which
contributes
onset
atopic
march.
It
clear
whether
change
an
outcome
or
cause
dysfunction
inflammation.
However,
cross-talk
between
commensals
immune
system
now
noticed,
alteration
believed
affect
maturation
innate
adaptive
immunity
during
early
life.
The
novel
concept
modifying
microbiome
by
applying
moisturizers
contain
nonpathogenic
biomass
probiotic
supplementation
years
may
be
preventive
therapeutic
option
high
risk
groups,
but
currently
lacks
evidence.
This
review
discusses
nature
flora
possible
mechanisms
skin–gut
interaction,
implications
correction
AD.
Nature Communications,
Journal Year:
2019,
Volume and Issue:
10(1)
Published: June 20, 2019
Abstract
Differential
abundance
analysis
is
controversial
throughout
microbiome
research.
Gold
standard
approaches
require
laborious
measurements
of
total
microbial
load,
or
absolute
number
microorganisms,
to
accurately
determine
taxonomic
shifts.
Therefore,
most
studies
rely
on
relative
data.
Here,
we
demonstrate
common
pitfalls
in
comparing
across
samples
and
identify
two
solutions
that
reveal
changes
without
the
need
estimate
load.
We
define
notion
“reference
frames”,
which
provide
deep
intuition
about
compositional
nature
In
an
oral
time
series
experiment,
reference
frames
alleviate
false
positives
produce
consistent
results
both
raw
cell-count
normalized
Furthermore,
consistent,
differentially
abundant
microbes
previously
undetected
independent
published
datasets
from
subjects
with
atopic
dermatitis.
These
methods
allow
reassessment
data
reproducible
sequencing
output
for
new
assays.
Allergy and Asthma Proceedings,
Journal Year:
2019,
Volume and Issue:
40(2), P. 84 - 92
Published: March 1, 2019
Atopic
dermatitis
(AD)
is
the
most
common
chronic
inflammatory
skin
disease.
Genetic
predisposition,
epidermal
barrier
disruption,
and
dysregulation
of
immune
system
are
some
critical
components
AD.
An
impaired
may
be
initial
step
in
development
atopic
march
as
well
AD,
which
leads
to
further
inflammation
allergic
sensitization.
Type
2
cytokines
interleukin
17
22
contribute
dysfunction
New
insights
into
pathophysiology
AD
have
focused
on
lipid
profiles,
neuroimmune
interactions,
microbial
dysbiosis.
Newer
therapeutic
strategies
focus
improving
function
targeting
polarized
pathways
found
Further
understanding
will
allow
us
achieve
a
more
precision
medicine
approach
prevention
treatment
British Journal of Dermatology,
Journal Year:
2017,
Volume and Issue:
178(5), P. 1083 - 1101
Published: Nov. 29, 2017
Atopic
dermatitis
is
a
chronic
inflammatory
skin
disease
that
may
require
systemic
therapy.
Ciclosporin
A
(CsA)
widely
used,
potent
immunosuppressant
but
it
not
effective
in
all
patients
with
atopic
dermatitis,
and
side‐effects
limit
its
use.
Dupilumab,
fully
human
anti‐interleukin
4
receptor‐alpha
monoclonal
antibody,
inhibits
signaling
of
IL‐4
IL‐13,
key
drivers
Type
2/Th2‐mediated
inflammation,
approved
the
U.S.A.
European
Union
for
treatment
inadequately‐controlled
moderate‐to‐severe
adults.
To
evaluate
efficacy
safety
dupilumab
concomitant
topical
corticosteroids
(TCS)
adults
inadequate
response
to/intolerance
CsA,
or
whom
CsA
was
medically
inadvisable.
In
this
16‐week,
double‐blind,
randomized,
placebo‐controlled,
phase
III
trial,
were
randomized
1
:
to
subcutaneous
300
mg
weekly
(qw)
every
2
weeks
(q2w)
placebo.
All
received
medium‐potency
TCS
from
Week
−2
through
16;
dosage
could
be
tapered
if
lesions
cleared,
stopped
adverse
reactions
TCS.
total,
390
screened,
325
318
completed
trial.
Treatment
groups
had
similar
baseline
characteristics.
Significantly
more
qw
+
q2w
achieved
≥
75%
improvement
Eczema
Area
Severity
Index
at
16
vs.
placebo
group
(primary
end
point)
(59·1%
62·6%
29·6%,
respectively;
P
<
0·001
TCS,
both
doses).
Other
clinical
outcomes
symptoms
significantly
improved
groups,
including
pruritus,
pain,
sleep
disturbance,
anxiety
depression,
quality
life
(QoL).
overall
rates
events
(qw
groups:
69·1%,
72·0%
69·4%,
respectively)
serious
(1·8%,
1·9%
1·9%,
respectively).
Conjunctivitis
frequent
TCS;
infections
Dupilumab
signs
QoL
history
No
new
signals
identified.